|Bid||7.45 x 800|
|Ask||7.46 x 800|
|Day's Range||7.40 - 7.86|
|52 Week Range||6.96 - 31.10|
|Beta (3Y Monthly)||1.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.56|
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.
Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.
Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
Acorda Therapeutics Inc NASDAQ/NGS:ACORView full report here! Summary * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for ACOR with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting ACOR. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ACOR had net inflows of $2.37 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.
Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.
The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer
Acorda Therapeutics, Inc. (ACOR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.
Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.
BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.
The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate achieves 44% ORR.